Literature DB >> 11353048

p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.

Y S Bian1, M C Osterheld, F T Bosman, J Benhattar, C Fontolliet.   

Abstract

The aim of the present study was to characterize expression and mutation of p53 during the neoplastic progression from Barrett's esophagus to adenocarcinoma and to test the reliability of immunohistochemistry for p53 overexpression as an indicator of p53 mutation in this context. The association of both gene mutation and protein accumulation with clinicopathological findings and survival was also studied. A total of 77 samples from 30 esophagectomy specimens with Barrett's esophagus and adenocarcinoma of patients in longitudinal clinical follow-up were analyzed. Different lesions (intestinal metaplasia, dysplasia, and adenocarcinoma) as well as normal squamous-cell esophageal epithelia were sampled from formalin-fixed, paraffin-embedded tissues by microdissection. Mutations in p53 Exons 5 to 9 were detected by polymerase chain reaction-single-strand conformation polymorphisms (PCR-SSCP) and confirmed by direct DNA sequencing. Nuclear accumulation of p53 protein was analyzed immunohistochemically from tissue sections adjacent to those used for microdissection. p53 gene mutations were found in 17 and p53 protein accumulation were found in 20 tumor samples. Of the 17 adenocarcinomas with a p53 mutation, 16 stained positive for p53 protein. p53 mutations were detected significantly more frequently in high-grade dysplastic than in low-grade dysplastic lesions (77% versus 29%, P < 0.01). In contrast, nuclear accumulation of p53 was detected in 85% of high-grade and 71% of low-grade dysplastic lesions. In eight cases with p53 mutation, the mutation identified in the tumors was also detected in premalignant lesions, mainly in high-grade dysplasia. In four cases of p53-mutated tumors, clones with different p53 mutations were detected in premalignant lesions. Neither p53 mutations nor p53 protein accumulations were found in metaplastic lesions. In summary, we found that p53 mutations occurred mainly during the transition from low-grade to high-grade dysplasia in the neoplastic progression of Barrett's esophagus but not in the nondysplastic Barrett's mucosa. Mutational analysis of p53 by PCR-SSCP and p53 accumulation by immunohistochemistry were mostly concordant in adenocarcinoma and high-grade dysplastic lesions but frequently discordant in low-grade dysplastic lesions. No correlation between p53 gene mutation or p53 accumulation and clinicopathological findings was observed in this study.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353048     DOI: 10.1038/modpathol.3880324

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  21 in total

1.  TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.

Authors:  L Murray; A Sedo; M Scott; D McManus; J M Sloan; L J Hardie; D Forman; C P Wild
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

2.  TP53 gene mutations are rare in nondysplastic Barrett's esophagus.

Authors:  Kamila Novotna; Marie Trkova; Alexandr Pazdro; Milan Smejkal; Alzbeta Soukupova; Daniela Kodetova; Premysl Smejkal; Zdenek Sedlacek
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

3.  Risk factors associated with Barrett's epithelial dysplasia.

Authors:  Mikiko Fujita; Yuri Nakamura; Saeko Kasashima; Maiko Furukawa; Ryoichi Misaka; Hikaru Nagahara
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

4.  Neoangiogenesis. Assessment in Esophageal Adenocarcinomas.

Authors:  Valeriu Ardeleanu; Laurian Francu; Costinela Georgescu
Journal:  Indian J Surg       Date:  2014-05-10       Impact factor: 0.656

5.  Uterine Carcinomas in Tetrabromobisphenol A-exposed Wistar Han Rats Harbor Increased Tp53 Mutations and Mimic High-grade Type I Endometrial Carcinomas in Women.

Authors:  Janice B Harvey; Tanasa S Osborne; Hue-Hua L Hong; Sachin Bhusari; Tai-Vu Ton; Arun R Pandiri; Tiwanda Masinde; June Dunnick; Shyamal Peddada; Susan Elmore; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2015-09-08       Impact factor: 1.902

6.  Intestinal metaplasia of the sinonasal mucosa adjacent to intestinal-type adenocarcinoma. A morphologic, immunohistochemical, and molecular study.

Authors:  Alessandro Franchi; Annarita Palomba; Lucia Miligi; Valentina Ranucci; Duccio Rossi Degli Innocenti; Antonella Simoni; Monica Pepi; Marco Santucci
Journal:  Virchows Arch       Date:  2014-11-28       Impact factor: 4.064

7.  Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression.

Authors:  Jonine D Figueroa; Mary Beth Terry; Marilie D Gammon; Thomas L Vaughan; Harvey A Risch; Fang-Fang Zhang; David E Kleiner; William P Bennett; Christine L Howe; Robert Dubrow; Susan T Mayne; Joseph F Fraumeni; Wong-Ho Chow
Journal:  Cancer Causes Control       Date:  2008-11-07       Impact factor: 2.506

8.  The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea.

Authors:  Nayoung Kim; Sung-Il Cho; Hye Seung Lee; Ji Hyun Park; Jee Hyun Kim; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  Dig Dis Sci       Date:  2009-01-29       Impact factor: 3.199

9.  Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology.

Authors:  G J S Jenkins; S H Doak; A P Griffiths; N Tofazzal; V Shah; J N Baxter; J M Parry
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 10.  Field defects in progression to gastrointestinal tract cancers.

Authors:  Carol Bernstein; Harris Bernstein; Claire M Payne; Katerina Dvorak; Harinder Garewal
Journal:  Cancer Lett       Date:  2007-12-31       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.